World Health Organization

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

New Report from Smoke Free Sweden: 1.4 Million Lives Could Be Saved If Brazil Adopted Sweden’s Smoke Free Strategy

Retrieved on: 
Wednesday, April 10, 2024
Other Health, Health, Retail, Tobacco, Oncology, Smoke, Mortality, WHO, World Health Organization, Death, Herbal cigarette, THR, Smoking, Harm reduction, Standstill

Almost 1.4 million Brazilian lives – equivalent to the population of Porto Alegre – could be saved if Brazil implemented Sweden’s ‘smoke free’ and tobacco harm reduction (THR) strategy, a major new report from Smoke Free Sweden reveals.

Key Points: 
  • Almost 1.4 million Brazilian lives – equivalent to the population of Porto Alegre – could be saved if Brazil implemented Sweden’s ‘smoke free’ and tobacco harm reduction (THR) strategy, a major new report from Smoke Free Sweden reveals.
  • The authors, from international movement Smoke Free Sweden , will launch their new report, Lives Saved: Integrating Harm Reduction Into Tobacco Control at an event in Brasilia today.
  • Currently, Brazil has a smoking rate of 13.4%, well above the World Health Organization’s official ‘smoke-free’ threshold of 5%.
  • However, this new report shows that by embracing the Swedish approach to THR, Brazil could save a huge number of lives.

Global Drive to ‘Quit Like Sweden’ Will Save Millions of Smokers’ Lives

Retrieved on: 
Wednesday, April 10, 2024
Tobacco, Retail, Health, Other Health, Swedish Medical Association, Mortality, Public, World Medical Association, MP, World Health Organization, Policy, Male, Innovation, Swedes, Developing country, Smoker, Federico Fernández, Smoking, Public policy, Notifiable disease, Smoke, QLS

INTERNATIONAL health experts today rallied behind a major new global effort to replicate Sweden’s success at eradicating smoking by embracing a comprehensive approach that could prevent many millions of premature deaths worldwide.

Key Points: 
  • INTERNATIONAL health experts today rallied behind a major new global effort to replicate Sweden’s success at eradicating smoking by embracing a comprehensive approach that could prevent many millions of premature deaths worldwide.
  • “It has set out a policy roadmap that should be treated as a gift to global public health and, potentially, one of the greatest ever breakthroughs in tackling non-communicable diseases (NCDs).
  • Misinformation and the impact on consumers: Miguel Okumura, THR Brasil and Alexandro Lucian, DIRETA.
  • The Swedish Experience’s life-saving potential for Brazil: Dr Delon Human, Dr Anders Milton and Prof. Dr. Erika Magalhaes Suzigan.

FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures Report

Retrieved on: 
Friday, April 26, 2024
Carbon, Carbon neutrality, Education, World Health Organization, NMPA, Malaria, HSI, Risk management, Culture, CSA, United Nations Global Compact, Climate, Disclosure, National Medical Products Administration, Sustainability, Create, Task force, Climate change, HKEX, Ecosystem, Health, SCLC, Biophysical environment, Temperature, AA, Cancer, Social, Hope, Policy, Paris Agreement, MSCI, Environment, Patient, Artesunate, ESG, The Bund Finance Center, Renewable energy

HONG KONG , April 26, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today issued the Environmental, Social and Governance (ESG) Report 2023 (the "ESG Report").

Key Points: 
  • HONG KONG , April 26, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today issued the Environmental, Social and Governance (ESG) Report 2023 (the "ESG Report").
  • Facing the increasingly severe challenges of global climate change, Fosun released its second Climate Information Disclosures Report with reference to the disclosure requirements of the Hong Kong Stock Exchange, the Task Force on Climate-Related Financial Disclosures ("TCFD") recommendations and IFRS S2 Climate-related Disclosures.
  • This year, the Group has actively pursued its carbon neutrality goal and issued the second Climate Information Disclosures Report.
  • For more information on Fosun's ESG, please refer to Fosun International's ESG Report 2023 posted on:
    The electronic copy of the 2023 Climate Information Disclosures Report is available on the Company's ESG webpage: ( https://en.fosun.com/esg/ )

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

Retrieved on: 
Thursday, April 25, 2024
Public, WHO, Safety, World Health Organization, City, Trial of the century, Half-life, Dengue virus, Polymer, Viral load, Patient, Fever Dream, Infection, Death, COVID-19, Paulo, Vaccine

Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval

Key Points: 
  • Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval
    SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in Brazil, which has the highest number of dengue cases and deaths in the world.
  • Hyundai Bioscience outlined two main reasons for choosing Brazil as its Dengue clinical trial regions:
    Firstly, Brazil has been the most affected country by the Dengue virus.
  • Hyundai Bioscience plans to conduct a basket-type clinical trial in Brazil (confirmatory clinical study for Dengue and exploratory clinical study for other mosquito-borne viral infections).
  • "The success of Dengue clinical study on our Niclosamide-based antiviral could lead to its emergency use authorization not only in Brazil but also in other countries.

EPA Announces Registration of Groundbreaking New Mosquito Control Solution

Retrieved on: 
Tuesday, April 23, 2024
Dengue fever, Family, Public, Genetically modified food, WHO, EPA, OMRI, World Health Organization, Environmental health, CDC, Disease, Bacteria, Notifiable disease, Male, Mosquito control, Female, Yellow, Chemical substance, Butterfly, Yellow fever, Wolbachia, Compatibility, Virus, Fever Dream, Bee, Multimedia, Community

This new mosquito control pesticide represents a significant advancement in mosquito control.

Key Points: 
  • This new mosquito control pesticide represents a significant advancement in mosquito control.
  • The WB1 pesticide specifically targets the Aedes aegypti mosquito, commonly known as the Yellow Fever mosquito.
  • "This approach offers targeted, species-specific mosquito control for communities and individuals, while maintaining the high safety standards expected by the EPA," Dobson emphasizes.
  • Effective Mosquito Control: WB1 Males effectively target and reduce populations of Aedes aegypti mosquitoes, the primary transmitter of Dengue fever.

University of Toronto scientists appointed as GSK chairs will advance drug delivery research and vaccine education tools for healthcare professionals

Retrieved on: 
Tuesday, April 23, 2024
Education, Addiction, University, Vaccination, Public, Pain, Cancer, Pharmacist, Cell, Attenuated vaccine, Fear, World Health Organization, The Hospital, Teaching, Infection, DSM-IV codes, University of Toronto, RNA, Research, Vaccine, CAMH, Therapy, Algorithm, Pressure, Mental health, GSK, CARD, COVID-19, Chemistry, Comfort, Genome, Health, Messenger, Student, Drug discovery, Dicarboxylic acid, Organization, Deep learning, Pharmaceutical industry

MISSISSAUGA, ON, April 23, 2024 /CNW/ - The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs.

Key Points: 
  • MISSISSAUGA, ON, April 23, 2024 /CNW/ - The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs.
  • Bowen Li, assistant professor at the Leslie Dan Faculty of Pharmacy, University of Toronto, and the Canada Research Chair in RNA Vaccines & Therapeutics is the new GSK Chair in Pharmaceutics and Drug Delivery.
  • They enable continuous advancement in research and teaching and signify a long-term commitment to a specific area of impact.
  • The GSK Chair in Vaccine Education and Practice-Oriented Tools was established by GSK and the Leslie Dan Faculty of Pharmacy in 2023 through a joint investment of $ 3 million.

Old Dominion University, HaptX, and Georgia Tech Win Grant Award for Project to Advance VR for Vision-Impaired

Retrieved on: 
Tuesday, April 23, 2024
Transfer, Education, National Eye, Paratriathlon, Bangladesh Technical Education Board, System, UI, World Health Organization, Electricity, Doctor of Philosophy, Research, Experiential learning, National Eye Institute, Associate professor, Visual impairment, Employment, VR, Google Images, Computer, National Institutes of Health, Georgia Tech, ODU, Obstetrics, Perception, Old Dominion University, Quality of life, Algorithm

REDMOND, Wash., April 23, 2024 /PRNewswire/ -- To investigate the use of advanced touch simulation for improving accessibility to digital information, the U.S. Department of Health and Human Services, National Institutes of Health, and National Eye Institute have awarded a Phase 1 Small Business Technology Transfer program grant to a research team from Old Dominion University (ODU), HaptX, and Georgia Institute of Technology to investigate "Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired." 

Key Points: 
  • "By unlocking access to the vast array of content previously inaccessible to people with limited sight, this project intends to make digital inclusivity a tangible reality."
  • Dr. Bruce Walker currently leads a project using HaptX Gloves for submarine safety training at Georgia Tech's Sonification Lab.
  • This new collaboration between HaptX, ODU, and Georgia Tech will bring dynamic Braille and much more to blind and low-vision users.
  • By bridging the accessibility gap for the visually impaired, the ODU-HaptX-Georgia Tech project opens new realms of engagement with spatial computing environments.

Eleanor Crook Foundation and CRI Foundation Partner with Action Against Hunger to Accelerate Global Uptake of Updated WHO Guidelines on Child Wasting

Retrieved on: 
Thursday, April 18, 2024
Climate change, UN, WHO, World Health Organization, Republic, Hunger, Lao people, Partnership, ECF, CRI, Research, Democratic republic, Guideline, Malnutrition, Child, Action Against Hunger, Death

Implementation of the newly updated WHO guidelines has the potential to dramatically reduce global child deaths through the application of updated evidence on the prevention and treatment of child wasting, the deadliest form of malnutrition.

Key Points: 
  • Implementation of the newly updated WHO guidelines has the potential to dramatically reduce global child deaths through the application of updated evidence on the prevention and treatment of child wasting, the deadliest form of malnutrition.
  • CRI Foundation is a co-investor in the partnership with Action Against Hunger, sharing a commitment to translate the guidelines into action and save lives.
  • We are grateful for the Eleanor Crook Foundation and Action Against Hunger for taking this much needed initiative and the support from our development partners."
  • "ECF is thrilled to partner with Action Against Hunger, working under the leadership of national governments, to put action behind these improved malnutrition treatment procedures.

Activists' abandon California decaf ban in face of scientific evidence, shift tactics to seek misleading warnings

Retrieved on: 
Wednesday, April 17, 2024
Conditional sentence, FDA, Hearing, Safety, Risk, World Health Organization, National Coffee Association, Food, American Cancer Society, NCA, American Institute, California State Assembly, Coffee, Drinking, Dietary supplement

In the final hours before the hearing, activist group and sponsor of California Assembly Bill 2066 the Clean Label Project abandoned the bill's proposed ban on the most common type of decaffeinated coffee and instead lobbied legislators to advance a last-minute amendment seeking misleading warning labels.

Key Points: 
  • In the final hours before the hearing, activist group and sponsor of California Assembly Bill 2066 the Clean Label Project abandoned the bill's proposed ban on the most common type of decaffeinated coffee and instead lobbied legislators to advance a last-minute amendment seeking misleading warning labels.
  • NCA President and CEO Bill Murray commented:
    "There was no evidence to support the proposed ban on European Method decaf, and there is equally no evidence at all to justify this last-minute shift to seeking misleading warning labels.
  • The fact is that decades of independent scientific evidence demonstrate that drinking European Method decaf, like all coffee, is associated with reduced risk of multiple cancers and chronic diseases.
  • NCA has also detailed the evidence establishing the safety of European Method decaf in comments to the U.S. Food and Drug Administration (FDA), opposing a separate but related activist petition seeking a federal decaf ban.